Enveric Biosciences Number Of Shares Shorted vs. Current Ratio

ENVB Stock  USD 0.33  0.01  3.13%   
Based on Enveric Biosciences' profitability indicators, Enveric Biosciences may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Enveric Biosciences' ability to earn profits and add value for shareholders. At present, Enveric Biosciences' Days Sales Outstanding is projected to decrease significantly based on the last few years of reporting. The current year's Days Of Sales Outstanding is expected to grow to 107.29, whereas Price To Sales Ratio is forecasted to decline to 0.33. At present, Enveric Biosciences' Income Tax Expense is projected to decrease significantly based on the last few years of reporting. The current year's Net Interest Income is expected to grow to 3,157, whereas Accumulated Other Comprehensive Income is forecasted to decline to (598.2 K).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.220.23
Sufficiently Down
Slightly volatile
For Enveric Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Enveric Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Enveric Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Enveric Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Enveric Biosciences over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities.
For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. If investors know Enveric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enveric Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.42)
Revenue Per Share
37.678
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.81)
Return On Equity
(2.06)
The market value of Enveric Biosciences is measured differently than its book value, which is the value of Enveric that is recorded on the company's balance sheet. Investors also form their own opinion of Enveric Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Enveric Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enveric Biosciences' market value can be influenced by many factors that don't directly affect Enveric Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enveric Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enveric Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enveric Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Enveric Biosciences Current Ratio vs. Number Of Shares Shorted Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Enveric Biosciences's current stock value. Our valuation model uses many indicators to compare Enveric Biosciences value to that of its competitors to determine the firm's financial worth.
Enveric Biosciences is rated # 3 in number of shares shorted category among its peers. It is rated # 4 in current ratio category among its peers . The ratio of Number Of Shares Shorted to Current Ratio for Enveric Biosciences is about  32,672 . At present, Enveric Biosciences' Current Ratio is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Enveric Biosciences' earnings, one of the primary drivers of an investment's value.

Enveric Current Ratio vs. Number Of Shares Shorted

Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Enveric Biosciences

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
272.16 K
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Enveric Biosciences

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
8.33 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).

Enveric Current Ratio Comparison

Enveric Biosciences is currently under evaluation in current ratio category among its peers.

Enveric Biosciences Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Enveric Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Enveric Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Enveric Biosciences' change in net profit over the period of time. It can combine multiple indicators of Enveric Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-569.7 K-598.2 K
Operating Income-16.4 M-15.6 M
Net Loss-17.3 M-16.4 M
Income Tax Expense28.9 K30.4 K
Income Before Tax-17.3 M-16.4 M
Total Other Income Expense Net-814.4 K-773.7 K
Net Interest IncomeK3.2 K
Net Loss-22.5 M-23.7 M
Net Loss-44.1 M-41.9 M
Interest Income3.3 KK
Change To Netincome41 M43.1 M
Net Loss(0.01)(0.01)
Income Quality 0.82  0.77 

Enveric Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Enveric Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Enveric Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Enveric Biosciences' important profitability drivers and their relationship over time.

Use Enveric Biosciences in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enveric Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enveric Biosciences will appreciate offsetting losses from the drop in the long position's value.

Enveric Biosciences Pair Trading

Enveric Biosciences Pair Trading Analysis

The ability to find closely correlated positions to Enveric Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enveric Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enveric Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enveric Biosciences to buy it.
The correlation of Enveric Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enveric Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enveric Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enveric Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Enveric Biosciences position

In addition to having Enveric Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Dividend Beast Thematic Idea Now

Dividend Beast
Dividend Beast Theme
An experimental equal-weighted theme of equities with high dividend yield and solid fundamentals based on Macroaxis rating system. The Dividend Beast theme has 69 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Dividend Beast Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Enveric Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enveric Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enveric Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enveric Biosciences Stock:
Check out Investing Opportunities.
For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
To fully project Enveric Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Enveric Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Enveric Biosciences' income statement, its balance sheet, and the statement of cash flows.
Potential Enveric Biosciences investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Enveric Biosciences investors may work on each financial statement separately, they are all related. The changes in Enveric Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Enveric Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.